The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: (JACC: CardioOncology State-of-the-Art Review April 2024)-Article: The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: JACC: CardioOncology State-of-the-Art Review

Article: The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: JACC: CardioOncology State-of-the-Art Review

Pdf Summary

The document explores the potential of Sodium-glucose cotransporter-2 (SGLT2) inhibitors in cardio-oncology, focusing on their ability to protect against cardiovascular side effects caused by cancer treatments and their potential anticancer effects. It discusses how these inhibitors, such as empagliflozin and dapagliflozin, can mitigate oxidative stress, inflammation, and ER stress induced by cancer therapies, as well as inhibit tumor growth and promote anticancer effects across different cancers. Additionally, the document highlights the cardioprotective properties of SGLT2 inhibitors in safeguarding against chemotherapy-induced cardiotoxicity through various pathways. By influencing inflammation, energy metabolism, oxidative stress, and ER stress, these inhibitors offer potential benefits in both cancer treatment and cardio-oncology. The document stresses the importance of further research, including randomized clinical trials, to fully assess the safety and efficacy of SGLT2 inhibitors in combination with standard cancer treatments. Ultimately, SGLT2 inhibitors hold promise in improving cardiac outcomes in patients undergoing cardiotoxic cancer treatments and potentially inhibiting cancer progression through their multifaceted mechanisms of action.

Keywords

Sodium-glucose cotransporter-2 inhibitors

SGLT2 inhibitors

Cardio-oncology

Cardiovascular side effects

Empagliflozin

Dapagliflozin

Oxidative stress

Inflammation

ER stress

Anticancer effects